Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (191-200 of 227) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaToni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Nature Medicine|May 31, 2020
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinomaDavid A Braun, Yue Hou, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research SummitToni K Choueiri, Laurence Albiges, Michael B Atkins, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Pageof 23

Showing results (191-200 of 227) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaToni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Nature Medicine|May 31, 2020
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinomaDavid A Braun, Yue Hou, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research SummitToni K Choueiri, Laurence Albiges, Michael B Atkins, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Pageof 23